Safety, tolerability, and Plasmodium falciparum transmissionreducing activity of monoclonal antibody TB31F: a singlecentre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

van der Boor, Saskia C.; Smit, Merel J.; van Beek, Stijn W.; Ramjith, Jordache; Teelen, Karina; van de Vegte-Bolmer, Marga; Van Gemert, Geert-Jan; Pickkers, Peter; Wu, Yimin; Locke, Emily; Lee, Shwu-Maan; Aponte, John; King, C. Richter; Birkett, Ashley J.; Miura, Kazutoyo; Ayorinde, Morolayo A.; Sauerwein, Robert W.; ter Heine, Rob; Ockenhouse, Christian F.; Bousema, Teun; Jore, Matthijs M.; McCall, Matthew B. B.

Safety, tolerability, and Plasmodium falciparum transmissionreducing activity of monoclonal antibody TB31F: a singlecentre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

Autor(en):

van der Boor, Saskia C.; Smit, Merel J.; van Beek, Stijn W.; Ramjith, Jordache; Teelen, Karina; van de Vegte-Bolmer, Marga; Van Gemert, Geert-Jan; Pickkers, Peter; Wu, Yimin; Locke, Emily; Lee, Shwu-Maan; Aponte, John; King, C. Richter; Birkett, Ashley J.; Miura, Kazutoyo; Ayorinde, Morolayo A.; Sauerwein, Robert W.; ter Heine, Rob; Ockenhouse, Christian F.; Bousema, Teun; Jore, Matthijs M.; McCall, Matthew B. B.

Tübinger Autor(en):

McCall, Matthew

Erschienen in:

Lancet Infectious Diseases (2022), Bd. 22, H. 11, S. 1596-1605

Verlagsangabe:

Oxford : Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1473-3099(22)00428-5

ISSN:

1473-3099